2-Amino[1,2,4]triazolo[1,5-c]quinazolines and Derived Novel Heterocycles: Syntheses and Structure-Activity Relationships of Potent Adenosine Receptor Antagonists

Medicinal chemistry of adenosine, P2Y and P2X receptors

(2016) Kenneth A. Jacobson et al.   NEUROPHARMACOLOGY

A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy

(2015) Robert D. Leone et al.   Computational and Structural Biotechnology Journal

1,3-Dialkyl-substituted tetrahydropyrimido[1,2-f]purine-2,4-diones as multiple target drugs for the potential treatment of neurodegenerative diseases

(2013) Pierre Koch et al.   BIOORGANIC & MEDICINAL CHEMISTRY

The Safety of an Adenosine A1-Receptor Antagonist, Rolofylline, in Patients with Acute Heart Failure and Renal Impairment

(2012) John R. Teerlink et al.   DRUG SAFETY

Cellular function and molecular structure of ecto-nucleotidases

(2012) Herbert Zimmermann et al.   Purinergic Signalling

Triazoloquinazolines as a novel class of phosphodiesterase 10A (PDE10A) inhibitors

(2011) Jan Kehler et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Effects of aminophylline on cognitive recovery after sevoflurane anesthesia

(2011) Mohamed R. El Tahan   Journal of Anesthesia

Recent advances in the multitarget-directed ligands approach for the treatment of Alzheimer's disease

(2011) Rafael León et al.   MEDICINAL RESEARCH REVIEWS

International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and Classification of Adenosine Receptors--An Update

(2011) B. B. Fredholm et al.   PHARMACOLOGICAL REVIEWS

Adenosine A2A Receptors and A2A Receptor Heteromers as Key Players in Striatal Function

(2011) Sergi Ferré et al.   Frontiers in Neuroanatomy

Recent developments in adenosine receptor ligands and their potential as novel drugs

(2010) Christa E. Müller et al.   BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES

A2A Receptor Ligands: Past, Present and Future Trends

(2010) C. Manera et al.   CURRENT TOPICS IN MEDICINAL CHEMISTRY

A2B Receptor Ligands: Past, Present and Future Trends

(2010) G. Ortore et al.   CURRENT TOPICS IN MEDICINAL CHEMISTRY

In Vivo Characterization of a Dual Adenosine A2A/A1Receptor Antagonist in Animal Models of Parkinson’s Disease

(2010) Brian C. Shook et al.   JOURNAL OF MEDICINAL CHEMISTRY

Human Follicular Lymphoma CD39+-Infiltrating T Cells Contribute to Adenosine-Mediated T Cell Hyporesponsiveness

(2009) S. P. Hilchey et al.   JOURNAL OF IMMUNOLOGY

1-Alkyl-8-(piperazine-1-sulfonyl)phenylxanthines: Development and Characterization of Adenosine A2BReceptor Antagonists and a New Radioligand with Subnanomolar Affinity and Subtype Specificity

(2009) Thomas Borrmann et al.   JOURNAL OF MEDICINAL CHEMISTRY

Recent improvements in the development of A2B adenosine receptor agonists

(2009) Pier Giovanni Baraldi et al.   Purinergic Signalling

Adenosine A2Areceptor antagonists exert motor and neuroprotective effects by distinct cellular mechanisms

(2008) Liqun Yu et al.   ANNALS OF NEUROLOGY

A novel adenosine A1 and A2A receptor antagonist ASP5854 ameliorates motor impairment in MPTP-treated marmosets: Comparison with existing anti-Parkinson's disease drugs

(2008) Takuma Mihara et al.   BEHAVIOURAL BRAIN RESEARCH

Dual inhibition of monoamine oxidase B and antagonism of the adenosine A2A receptor by (E,E)-8-(4-phenylbutadien-1-yl)caffeine analogues

(2008) Judey Pretorius et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Adenosine Receptor Antagonists:  Translating Medicinal Chemistry and Pharmacology into Clinical Utility

(2008) Pier Giovanni Baraldi et al.   CHEMICAL REVIEWS

An Update on Adenosine A2A-Dopamine D2 Receptor Interactions: Implications for the Function of G Protein-Coupled Receptors

(2008) S. Ferre et al.   CURRENT PHARMACEUTICAL DESIGN